We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Filtering Donor Blood Reduces Complications in the Recipient

By LabMedica International staff writers
Posted on 06 Jul 2010
When foreign white cells were filtered from donor blood, there were dramatically fewer cardiopulmonary complications in recipients.

An observational study was conducted during the seven years before and after 2000, when the University of Rochester Medical Center (URMC; Rochester, NY, USA) introduced universal leukoreduction, a process that filters the white cells from blood to be used for transfusions. More...
Investigators looked at the number of reports of transfusion reactions during the 14-year period, and divided them by the total number of blood components transfused (778, 559).

Rates of acute, transfusion-related lung injury dropped 83 % in the years after filtering took place, and transfusion-associated circulatory overload declined 49 %, when compared to the rates prior to the year 2000. Both conditions are rare, but are among the most common causes of death following a transfusion.

"These data are very exciting because we described two unexpected and unexplained associations between adverse reactions and leukoreduction," said Neil Blumberg, M.D. who led the study. "However, our observations do not prove cause and effect, and therefore require further investigation before we can say with certainty that leukoreduction is responsible for so many fewer cardiopulmonary complications."

The [U.S.] Centers for Disease Control and Prevention (Atlanta, GA, USA) is introducing a new blood surveillance system to track severe transfusion reactions, which should provide more detailed information to support or refute the URMC study.

The study appears in the June 18, 2010, online edition of the journal Transfusion.

Work done at URMC also has supported keeping transfusions to an absolute minimum. Dr. Blumberg's evidence-based stance on the judicious use of transfusions and safer techniques has contributed greatly to the national and international dialogue on reducing in-hospital infections rates and controlling costs.

Related Links:
University of Rochester Medical Center
U.S. Centers for Disease Control and Prevention




New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
POC Immunoassay Analyzer
Procise DX
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.